Advance Search
JIANG Qiuli. Effect of levonorgestrel intrauterine sustained-releasesystem combined with low-dose mifepristone in the treatment of adenomyosis[J]. Journal of Clinical Medicine in Practice, 2019, 23(19): 65-68. DOI: 10.7619/jcmp.201919017
Citation: JIANG Qiuli. Effect of levonorgestrel intrauterine sustained-releasesystem combined with low-dose mifepristone in the treatment of adenomyosis[J]. Journal of Clinical Medicine in Practice, 2019, 23(19): 65-68. DOI: 10.7619/jcmp.201919017
shu

Effect of levonorgestrel intrauterine sustained-releasesystem combined with low-dose mifepristone in the treatment of adenomyosis

  • Department of Gynecology, Hanzhong Central Hospital, Hanzhong, Shaanxi, 723000

More Information
  • Received Date: June 03, 2019
  • Accepted Date: August 19, 2019
  • Available Online: February 28, 2021
  • Published Date: October 14, 2019
    Graphical Abstract
    • Abstract
  •   Objective  To investigate the effect of levonorgestrel intrauterine sustained-release system (LNG-IUS) combined with mifepristone in the treatment of adenomyosis.
      Methods  A total of 94 patients with adenomyosis admitted to our hospital were randomly divided into control group and observation group, with 47 cases in each group. The control group was treated with LNG-IUS alone, while the observation group was treated with LNG-IUS combined with low-dose mifepristone. All patients were followed up for 4 months. The serum carbohydrate antigen 125 (CA125), dysmenorrhea Visual Analogue Scale (VAS), changes of menstrual volume and results of B ultrasonography were compared before and after treatment, and the clinical efficacy and treatment safety were evaluated.
      Results  After treatment, the serum CA125, dysmenorrhea VAS score, menstrual amount, uterine volume and endometrial thickness of the two groups decreased significantly compared with treatment before(P < 0.05). Compared with the control group, the above indexes of the study group decreased more significantly (P < 0.05). The total effective rate was significantly higher than that of the control group (95.74% vs. 80.85%, P < 0.05). There were only a few mild adverse reactions, and higher safety in the two groups.
      Conclusion  LNG-IUS combined with low-dose mifepristone can significantly reduce serum CA125 level, improve clinical symptoms in patients with adenomyosis, and has higher safety.
    • FullText(HTML)
    • References (10)
  • [1]
    石一复.有关子宫腺肌症一些问题的商榷[J].中国计划生育和妇产科, 2018, 10(1): 3-6. https://www.cnki.com.cn/Article/CJFDTOTAL-JHFC201801002.htm
    [2]
    吴亚玲, 李合欣.左炔诺孕酮宫内缓释系统治疗子宫腺肌症195例临床分析[J].中国药物与临床, 2018, 18(3): 454-455. https://www.cnki.com.cn/Article/CJFDTOTAL-YWLC201803063.htm
    [3]
    刘玉婷, 王姝, 孙婷婷, 等.子宫腺肌病相关的分子机制研究进展[J].中华妇产科杂志, 2019, 54(2): 135-138.
    [4]
    张彩玩, 邓森灵.子宫腺肌病患者应用腹腔镜子宫楔形切除术并术后阴道置放左炔诺孕酮宫内缓释系统治疗效果观察[J].中国性科学, 2018, 27(4): 106-108. https://www.cnki.com.cn/Article/CJFDTOTAL-XKXZ201804035.htm
    [5]
    周敏, 张呈艳, 朱彩芳, 等.左炔诺孕酮宫内缓释系统治疗子宫内膜增生的临床疗效及对患者性激素和性激素受体水平的影响[J].中国妇幼保健, 2017, 32(8): 1771-1773. https://www.cnki.com.cn/Article/CJFDTOTAL-ZFYB201708061.htm
    [6]
    段金花.小剂量米非司酮治疗子宫腺肌症的疗效及用药安全性分析[J].实用妇科内分泌杂志:电子版, 2017, 4(15): 41-44. https://www.cnki.com.cn/Article/CJFDTOTAL-FKDZ201715023.htm
    [7]
    冯华萍, 赵绍杰, 唐艳.左炔诺孕酮缓释系统联合达菲林治疗子宫腺肌症的疗效及对血清CA125 CA199 HE4的影响[J].河北医学, 2019, 25(1): 5-9. https://www.cnki.com.cn/Article/CJFDTOTAL-HCYX201901001.htm
    [8]
    田颖.左炔诺孕酮宫内节育系统联合米非司酮治疗痛经及经量增多子宫腺肌症的临床疗效观察[J].实用医技杂志, 2018, 25(11): 97-98. https://www.cnki.com.cn/Article/CJFDTOTAL-SYYJ201811060.htm
    [9]
    袁学芝, 郭金荣.米非司酮联合曼月乐对功血患者雌孕激素受体及子宫内膜b FGF、VEGF表达的影响[J].中华保健医学杂志, 2019, 21(1): 60-63. https://www.cnki.com.cn/Article/CJFDTOTAL-JFJB201901043.htm
    [10]
    吴晓虹, 张文杰, 武冬娜.子宫腺肌病患者采用曼月乐联合小剂量米非司酮治疗的效果及对血清神经生长因子可溶性CD147血管内皮生长因子水平变化的影响[J].河北医学, 2019, 25(1): 54-58. https://www.cnki.com.cn/Article/CJFDTOTAL-HCYX201901013.htm
    • Related Articles

Catalog

    Get Citation
    PDF
    XML
    Article views (292) PDF downloads (4) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return